Abstract:Background: The development of drug resistance and the persistence of leukemia stem cells are major obstacles for the use of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML). The induction of autophagic death in tumor cells represents a new route for leukemia treatment. Our previous study showed that infection of CML cells with oncolytic viruses carrying the autophagy gene Beclin1 downregulated BCR/ABL protein expression and significantly increased the killing effect of the oncolytic viruses on CML cells via autophagy activation. However, the specific molecular mechanisms underlying the regulation of BCR/ABL and Beclin1-dependent CML cell killing remain unclear. Methods: A physical interaction between BCR/ABL and Beclin1 was characterized via GST-pulldown, co-IP and dual-luciferase reporter assays. Cell proliferation was examined via CCK-8 and clone formation assays. The expression levels of the related proteins were measured via Western blotting. Autophagosomes were observed under transmission electron microscopy. Lentiviral vectors carrying Atg7/UVRAG shRNA or the Beclin1 gene were used to modulate the expression levels of the indicated genes. Immunofluorescence were performed to examine colocalization of BCR/ABL and p62/SQSTM1. CD34(+)CD38(-) cells were isolated from bone marrow samples from CML patients via fluorescence-activated cell sorting. Results: In this study, we observed that Beclin1 directly interacts with BCR/ABL. Beclin1 inhibited the activity of the BCR/ABL promoter to downregulate the level of BCR/ABL protein and to promote the downstream colocalization of p62/SQSTM1 and BCR/ABL to autolysosomes for degradation via activation of the autophagy signaling pathway. In CML cell lines, primary cells and CD34(+)CD38(-) leukemia stem cells, Beclin1 overexpression significantly inhibited cell growth and proliferation and induced autophagy. Conclusion: Taken together, our results suggest that autophagy induction via Beclin1 overexpression might offer new approaches for treating TKI-resistant CML and for promoting the clearance of leukemia stem cells, both of which have important clinical implications.

[Study on the Mechanisms of Imatinib-Resistance of Cancer Stem-Like Cells in K562/Vp16 Cell Line].

The Study of Resistant Mechanisms and Reversal in an Imatinib Resistant Ph+ Acute Lymphoblastic Leukemia Cell Line.

Stromal Cells Attenuate the Cytotoxicity of Imatinib on Philadelphia Chromosome-Positive Leukemia Cells by Up-Regulating the VE-cadherin/β-catenin Signal

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

[A Preliminary Study on Mechanisms for Resistance of CML Patient BM-derived Bcr/abl+ and Flk1+CD31-CD34- Stem Cells to STI571 in Vitro].

Inducible SHP-2 Activation Confers Resistance to Imatinib in Drug-Tolerant Chronic Myeloid Leukemia Cells

[The Relationship Between Multi-Drug Resistance and Proportion of Leukemia Stem Cells and Expression of Drug Transporters in Drug-Resistant Leukemia K562/ADM Cells].

[Multidrug Resistant Gene MDR1 Contributes to Development of Imatinib-Resistance in Ph (+) Acute Lymphoblastic Leukemia Cell Line SUP-BS15RI].

[Establishment of an Imatinib Resistance Cell Line K562R and Its Resistant Principia].

Exosomes Derived from Imatinib-Resistant Chronic Myeloid Leukemia Cells Mediate a Horizontal Transfer of Drug-Resistant Trait by Delivering Mir-365

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments

Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.

[Transcriptome Analysis of Chronic Myelogenous Leukemia Cell Line with Imatinib Resistance]

[Study on the Mechanism of Imatinib-Induced Resistance in Gastrointestinal Stromal Tumors].

[Effect of ZD6474 on the Proliferation of Imatinib-Resistant K562 Cells].

Chronic Imatinib Mesylate Exposure Leads to Reduced Intracellular Drug Accumulation in K562 Cells Measured by High-Performance Liquid Chromatography.

Effect of p16 gene cloning combined with imatinib on chronic myeloid leukemia K562 cell line

High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia

Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia

Low-dose Staurosporine Selectively Reverses BCR-ABL-independent IM Resistance Through PKC-α-mediated G2/M Phase Arrest in Chronic Myeloid Leukaemia

Targeting SOS1 Overcomes Imatinib Resistance with BCR-ABL Independence Through Uptake Transporter SLC22A4 in CML